Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

2014 ◽  
Vol 60 (4) ◽  
pp. 951-956 ◽  
Author(s):  
Yun-Seong Kang ◽  
Hyoung Ho Moon ◽  
Seung Eun Lee ◽  
Yun Jeong Lim ◽  
Hyoun Woo Kang
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Experience ◽  
Bowel Disease ◽  
Case Series ◽  
Inflammatory Bowel

Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series

2021 ◽  
Author(s):  
Alejandro Llanos-Chea ◽  
Jason M. Shapiro ◽  
Rachel W. Winter ◽  
Logan Jerger ◽  
Timothy Menz ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Case Series ◽  
Inflammatory Bowel ◽  
Pediatric Onset

scholarly journals Vitamin C Deficiency in Inflammatory Bowel Disease: The Forgotten Micronutrient

2021 ◽  
Author(s):  
Katie A Dunleavy ◽  
Ryan C Ungaro ◽  
Laura Manning ◽  
Stephanie Gold ◽  
Joshua Novak ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Vitamin C ◽  
Bowel Disease ◽  
Fruits And Vegetables ◽  
Nutritional Assessment ◽  
Care Center ◽  
Tertiary Care ◽  
Case Series ◽  
Vitamin C Deficiency ◽  
Inflammatory Bowel

Abstract Background Micronutrient deficiencies are common in patients with inflammatory bowel disease (IBD). To date, the literature has focused on vitamin D, vitamin B12, and iron deficiencies. Methods We report a case series of 20 patients with IBD and vitamin C deficiency treated at a single tertiary care center. Results Sixteen (80%) patients had symptoms of clinical scurvy, including arthralgia, dry brittle hair, pigmented rash, gingivitis, easy bruising and/or brittle nails. Eighteen patients underwent a nutritional assessment, 10 (56%) patients reported complete avoidance of fruits and vegetables, and 3 (17%) reported reduced intake of fruits and vegetables. Conclusions Vitamin C deficiency should be considered in IBD patients, particularly those with reduced fruit/vegetable intake, as it can lead to significant signs and symptoms.

Mo1884 - Drug Survival of Vedolizumab-Treated Inflammatory Bowel Disease Patients in a Nationwide Observational Cohort Study: ICC Case Series

2018 ◽  
Vol 154 (6) ◽  
pp. S-838
Author(s):  
Vince Biemans ◽  
Christien Janneke Van Der Woude ◽  
Gerard Dijkstra ◽  
Andrea Van Der Meulen ◽  
Bas Oldenburg ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Bowel Disease ◽  
Case Series ◽  
Observational Cohort Study ◽  
Drug Survival ◽  
Observational Cohort ◽  
Inflammatory Bowel

Long-term clinical experience with vedolizumab for the treatment of inflammatory bowel disease

2011 ◽  
Vol 17 (suppl_1) ◽  
pp. S56-S56
Author(s):  
A Parikh ◽  
T Leach ◽  
I Fox ◽  
J Xu ◽  
M Patella ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Experience ◽  
Bowel Disease ◽  
Inflammatory Bowel

Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease

2018 ◽  
Vol 41 (10) ◽  
pp. 629-635
Author(s):  
Eugenia Sánchez Rodríguez ◽  
Raquel Ríos León ◽  
Francisco Mesonero Gismero ◽  
Agustín Albillos ◽  
Antonio Lopez-Sanroman
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Experience ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
Metabolite Measurement

A Case Series of De Novo Inflammatory Bowel Disease After Kidney Transplantation

2013 ◽  
Vol 45 (3) ◽  
pp. 1084-1087 ◽  
Author(s):  
P. Azevedo ◽  
C. Freitas ◽  
P. Aguiar ◽  
H. Silva ◽  
T. Santos ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Kidney Transplantation ◽  
Bowel Disease ◽  
De Novo ◽  
Case Series ◽  
Inflammatory Bowel

Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists

2018 ◽  
Vol 52 (6) ◽  
pp. 571-579 ◽  
Author(s):  
Sean M. McConachie ◽  
Sheila M. Wilhelm ◽  
Ashish Bhargava ◽  
Pramodini B. Kale-Pradhan
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Opportunistic Infections ◽  
Case Series ◽  
Infectious Risk ◽  
Increased Risk ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Meta Analyses

Objective: To review the mechanism and association of infectious risk among the tumor-necrosis factor α (TNF-α) antagonists used in inflammatory bowel disease. Data Sources: A PubMed literature search was performed using the following search terms: infliximab, adalimumab, certolizumab, golimumab, inflammatory bowel disease, crohn’s, ulcerative colitis, adverse effects, adverse events, safety, and infection. Study Selection and Data Extraction: Meta-analyses and cohort studies with outcomes pertaining to quantitative infectious risk were reviewed. Case reports and case series describing association between TNF-α inhibitors and infection were also reviewed. Data Synthesis: A total of 7 recent meta-analyses of randomized trials demonstrate inconclusive association of infection with TNF-α antagonists. Registry data suggest that medications carry an independent risk of opportunistic infections. Risk factors for infection include older age, malnutrition, diabetes, and possibly combination therapy. Reported infections vary widely but include intracellular and granulomatous bacteria, viruses, and fungi. Conclusion: TNF-α antagonists are associated with an increased risk of opportunistic infection, although this risk has not been demonstrated conclusively in randomized controlled trials. Knowledge of concomitant risk factors, mechanism of infectious risk, and available treatment options can improve patient care in the clinical setting.

Sign in / Sign up

Export Citation Format

Share Document